Riluzole for treating spasticity in patients with chronic traumatic spinal cord injury: Study protocol in the phase ib/iib adaptive multicenter randomized controlled RILUSCI trial - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue PLoS ONE Année : 2023

Riluzole for treating spasticity in patients with chronic traumatic spinal cord injury: Study protocol in the phase ib/iib adaptive multicenter randomized controlled RILUSCI trial

Maëva Cotinat
Isabelle Boquet
Moreno Ursino
Elisabeth Jouve
  • Fonction : Auteur
Corinne Alberti
  • Fonction : Auteur
Olivier Blin
  • Fonction : Auteur

Résumé

Satisfactory treatment is often lacking for spasticity, a highly prevalent motor disorder in patients with spinal cord injury (SCI). Low concentrations of riluzole potently reduce the persistent sodium current, the post-SCI increase in which contributes to spasticity. The repurposing of this drug may therefore constitute a useful potential therapeutic option for relieving SCI patients suffering from chronic traumatic spasticity. Objective RILUSCI is a phase 1b-2b trial designed to assess whether riluzole is a safe and biologically effective means of managing spasticity in adult patients with traumatic chronic SCI.
Fichier principal
Vignette du fichier
journal.pone.0276892.pdf (920.95 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Licence : CC BY - Paternité

Dates et versions

hal-04087364 , version 1 (03-05-2023)

Licence

Paternité

Identifiants

Citer

Maëva Cotinat, Isabelle Boquet, Moreno Ursino, Cécile Brocard, Elisabeth Jouve, et al.. Riluzole for treating spasticity in patients with chronic traumatic spinal cord injury: Study protocol in the phase ib/iib adaptive multicenter randomized controlled RILUSCI trial. PLoS ONE, 2023, 18, ⟨10.1371/journal.pone.0276892⟩. ⟨hal-04087364⟩
37 Consultations
15 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More